Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis

Add-on agents with alpha-2 antagonist activity appear to improve the efficacy of D2 antagonists for the treatment of schizophrenia by reducing negative symptoms. These results support conducting a more definitive confirmatory clinical trial.